There is more to the comparison, and in the sections below, we discuss why we think BMY will outperform JNJ in the next three ...

Tyler Sandahl, PharmD, of Mayo Clinic, and Michael Byrne, DO, of Tennessee Oncology, discuss practical advice for bringing ...

We recently compiled a list of the 10 Best Up and Coming Stocks To Buy According to Analysts. In this article, we are going ...

Many of you may remember from this column that I have multiple myeloma, or cancer of the bone marrow. In January, I will be headed to UVA hospital for a ...

Samer A. Al’Hadidi, MD, discusses factors influencing early use of chimeric antigen receptor T-cell therapy in patients with ...

Researchers sought to determine whether cilta-cel would have similar results in a real-world RRMM population as in a clinical trial population.

Roche's acquisition of Poseida Therapeutics (PSTX) for $1.5B joins the growing trend of cell therapies in M&A activities. Check out my review of this deal.

The deal suggests Roche sees substantial promise in Poseida’s technology, as the offer is 215% above the biotech’s closing ...

GSK plc GSK announced that the FDA accepted its biologics license application (BLA) seeking approval for the Blenrep ...

Adaptive Biotechnologies posted strong Q3 results, beating expectations and reducing losses. Read why I maintain a Hold ...

Despite challenges such as high attrition rates and adverse events, the trial highlights the value of established therapies ...